Fig. 2From: Safety, tolerability, pharmacokinetics, and antiviral activity of the novel core protein allosteric modulator ZM-H1505R (Canocapavir) in chronic hepatitis B patients: a randomized multiple-dose escalation trialMean values of the plasma concentrations of Canocapavir over time in each treatment cohort (mean ± standard deviation)Back to article page